Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid after denosumab in postmenopausal osteoporosis
NCT05361408Phase 4Completed
- Sponsor
- Yonsei University
- Start
- Feb 2022
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
Phase 4, open-label trial of zoledronic acid in osteoporosis, sponsored by Yonsei University. Primary endpoint: Bone Mineral Density of the Lumbar Spine at 1 year. Started Feb 2022; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05361408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361408.